Abumayyaleh Mohammad, El-Battrawy Ibrahim, Behnes Michael, Borggrefe Martin, Akin Ibrahim
First Department of Medicine, Medical Faculty Mannheim, University Heidelberg, Mannheim, 68167, Germany.
DZHK (German Center for Cardiovascular Research), Partner Site, Heidelberg-Mannheim, Mannheim, Germany.
Future Cardiol. 2020 Jul;16(4):227-236. doi: 10.2217/fca-2020-0002. Epub 2020 Mar 18.
Heart failure (HF) is one of the most common reasons for hospital admission in western countries. The measurement of the left ventricular ejection fraction is essential for the classification of HF and deciding on HF treatment. The treatment of HF has been improved in both diagnostic and therapeutic fields over the past two decades. The angiotensin receptor-neprilysin inhibitor decreased the cardiovascular mortality in patients with chronic HF with reduced ejection fraction. Sacubitril/valsartan (LCZ696) improves the imbalance between the renin-angiotensin-aldosterone and natriuretic peptide systems. We present the clinical efficacy, real-world experience, safety and tolerability, the relevance of etiology of cardiomyopathy, and gender differences and regulatory affairs of LCZ696 in the treatment of patients with HF with reduced ejection fraction.
心力衰竭（HF）是西方国家住院治疗最常见的原因之一。左心室射血分数的测量对于HF的分类和治疗决策至关重要。在过去二十年中，HF的治疗在诊断和治疗领域均有所改善。血管紧张素受体脑啡肽酶抑制剂降低了射血分数降低的慢性HF患者的心血管死亡率。沙库巴曲缬沙坦（LCZ696）改善了肾素-血管紧张素-醛固酮系统和利钠肽系统之间的失衡。我们介绍了LCZ696在治疗射血分数降低的HF患者中的临床疗效、真实世界经验、安全性和耐受性、心肌病病因的相关性、性别差异及监管事务。
